TherapeuticsMD
TXMD
43 hedge funds and large institutions have $13.8M invested in TherapeuticsMD in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 19 closing their positions.
1.98% less ownership
Funds ownership: 23.96% → 21.98% (-2%)
17% less funds holding
Funds holding: 52 → 43 (-9)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
32% less capital invested
Capital invested by funds: $20.2M → $13.8M (-$6.47M)
33% less call options, than puts
Call options by funds: $2.27M | Put options by funds: $3.4M
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.96M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$672K |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$327K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$288K |
| 5 |
Millennium Management
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$983K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$853K |
| 3 |
E
Ergoteles
New York
|
-$843K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$729K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$596K |
TXMD Hedge Fund Activity: Q3 2022 in Review
43 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2022, worth a combined $13.8M — down 32% from $20.2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of TXMD and 11 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $2.96M. The largest seller was BlackRock, cutting an estimated $983K.
- 43 institutional investors held TherapeuticsMD (TXMD) as of Q3 2022, down from 52 in Q2 2022.
- Funds reported $13.8M of TherapeuticsMD stock for Q3 2022, down 32% quarter-over-quarter.
- 11 funds opened new TherapeuticsMD positions in Q3 2022 and 19 closed out, a net change of -8 holders.
- The largest TherapeuticsMD buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $2.96M added.
- The largest TherapeuticsMD seller in Q3 2022 was BlackRock, an estimated $983K sold.
Based on aggregated 13F filings for Q3 2022.